Perspectives on bifidobacteria as biotherapeutic agents in gastrointestinal health.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation.Kidney international · 2010
   Trial
2. Effect of special Hungarian probiotic kefir on faecal microflora.World journal of gastroenterology · 2006
   Trial
3. Development of a luciferase-based reporter system to monitor Bifidobacterium breve UCC2003 persistence in mice.BMC microbiology · 2008
   Article
4. In vivo effects of bifidobacteria and lactoferrin on gut endotoxin concentration and mucosal immunity in Balb/c mice.Digestive diseases and sciences · 2004
   Article
5. Bifidobacterium bifidum monoassociation of gnotobiotic mice: effect on enterocyte brush-border enzymes.Folia microbiologica · 2001
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as